Under a $1 billion acquisition agreement, Novo Nordisk A/S will investigate a potential first-in-class small molecule CB1 receptor blocker as a treatment for obesity.
List view / Grid view
A positive opinion has been adopted by the CHMP for a citrate-free high concentration formulation of its biosimilar Hyrimoz® (adalimumab).
Schizophrenia and bipolar I disorder patients can be offered Rykindo® as a bi-weekly long-acting risperidone injection, as a result of the FDA's approval.
Safety results from a first-in-human study showed that orally inhaled murepavadin, a novel macrocycle compound, was well tolerated at all dose levels.
HIV patients received real-time antiretroviral dosage data from an innovative edible sensor in a clinical trial.
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
Pipe-307 demonstrated linear pharmacokinetic (PK) data consistent with pre-clinical modelling and was generally well tolerated at all doses in 70 healthy adult volunteers.
Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients, according to new Phase III data.
Researchers have compiled a repository of clinical and in vitro data for excipients to enable their potential to interact with drugs to be modelled.
Nemera offers four product platforms for pen development and manufacturing. These include reusable and disposable devices which are designed for various therapies to meet key users’ needs.
Researchers have demonstrated that bioavailability tests in patients to reveal anti-drug antibody levels could aid personalised medicine.
A growing requirement for drugs to be safe and effective is being driven by public awareness and understanding. Nilesh Londhe discusses why this pharmacovigilance is increasing.
Application Note: Sensitive quantitation of the ADC ado-trastuzumab emtansine free cytotoxic drug DM1 in serum using MicroLC-MS
Antibody-drug conjugates (ADC’s) are targeted cancer therapeutics that deliver a cytotoxic agent, the payload, to the tumour.
A group of researchers is showing how artificial intelligence approaches can help identify cause-effect relationships within data...